STAT+: What Pfizer’s decision to pull its sickle cell drug means for patients, the company, and the FDA
STAT
SEPTEMBER 26, 2024
Pfizer’s decision Wednesday to pull its sickle cell pill off the market because of safety concerns shocked advocates and doctors, leaving many searching for answers and scrambling for ways to notify their patients about a drug that has long divided the community. The move underscored the severity of the risks recently seen in studies of the drug, Oxbryta , in which researchers have reported a number of deaths among patients who were receiving it.
Let's personalize your content